Compare ACCL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | NSRX |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 37.1M |
| IPO Year | 2024 | 2024 |
| Metric | ACCL | NSRX |
|---|---|---|
| Price | $2.40 | $2.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 1.7K | ★ 14.0K |
| Earning Date | 11-27-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $1.98 |
| 52 Week High | $4.98 | $9.50 |
| Indicator | ACCL | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 29.72 |
| Support Level | $1.33 | $2.41 |
| Resistance Level | $2.89 | $3.61 |
| Average True Range (ATR) | 0.06 | 0.23 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 21.98 | 4.49 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.